Yearly Archives: 2022

In the bustling biotech space, a couple years can feel like an eternity — but for an Atlas Venture-backed neurology player with a novel spin on R&D, a few quiet years aren’t the worst thing in the world.

As pharma continues to seek new breakthroughs across drug modalities, few areas have garnered more interest than protein degradation. And Amgen is taking a flyer out on a small biotech that thinks its broad approach to degrader R&D could spell a fruitful relationship with the drug giant.